OTS have already identified a number of cancer-specific-genes that would be applicable for development of molecular-targeted anti-cancer therapies. OTS has been pursuing the medicinal discovery research with understanding the subcellular localization, mode of function, and immunogenicity of the target cancer-specific-genes.
- Investor Relations18/07/2017Announcement of collaboration with three medical corporations for development of dendritic cell-based cancer immunotherapy
- Business News13/07/2017Announcement of the article related our Special Scientific Advisor in Japan Times
- Investor Relations13/07/2017Patent Registration for MELK-specific inhibitors in Japan
Our service offers comprehensive analysis of TCR repertoire from blood and tissue samples using next generation sequencing technology. A detailed data analysis will be performed. We ensure that we will perform this service consistently, from sample preparation to delivering results.
and Safer Cancer Treatments
Pursuing “To develop anti-cancer medicine and anti-cancer therapy with high efficacy and minimum risk of adverse events, and to win the war against cancer”, OTS has been conducting research and development, by collaborating with Professor Yusuke Nakamura, a genomics pioneer.